Engineers Gate Manager LP Makes New Investment in Pharvaris N.V. $PHVS

Key Points

• Engineers Gate Manager LP acquired 33,059 Pharvaris shares worth approximately $1.14 million in the second quarter, while several other institutional investors also opened new positions.
• Pharvaris reported a quarterly loss of $0.81 per share, missing analysts’ estimate of a $0.75 loss. Analysts nonetheless maintain a “Moderate Buy” consensus, with an average price target of $59.87 versus the stock’s $36.37 opening price.
• Insiders sold 221,112 shares worth approximately $8.21 million during the last quarter, including significant sales by President Peng Lu and Director Robert Glassman.

Engineers Gate Manager LP acquired a new stake in shares of Pharvaris N.V. (NASDAQ:PHVS - Free Report) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 33,059 shares of the company's stock, valued at approximately $1,143,000. Engineers Gate Manager LP owned 0.05% of Pharvaris at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of PHVS. Quantbot Technologies LP purchased a new stake in Pharvaris during the 2nd quarter valued at $41,000. CoreCap Advisors LLC purchased a new position in Pharvaris during the second quarter worth $93,000. Nano Cap New Millennium Growth Fund L P purchased a new position in Pharvaris during the fourth quarter worth $139,000. Public Employees Retirement System of Ohio purchased a new position in Pharvaris during the second quarter worth $196,000. Finally, Algert Global LLC bought a new position in Pharvaris during the second quarter valued at $238,000.

Pharvaris Stock Performance

PHVS stock opened at $36.37 on Friday. Pharvaris N.V. has a one year low of $20.65 and a one year high of $43.25. The firm has a market cap of $2.38 billion, a price-to-earnings ratio of -11.92 and a beta of -2.33. The firm has a 50-day simple moving average of $35.37 and a two-hundred day simple moving average of $31.73.

Pharvaris (NASDAQ:PHVS - Get Free Report) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06). As a group, equities analysts predict that Pharvaris N.V. will post -3.12 earnings per share for the current fiscal year.

Insider Activity

In related news, President Peng Lu sold 15,000 shares of the company's stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $40.68, for a total transaction of $610,200.00. Following the transaction, the president directly owned 65,179 shares of the company's stock, valued at $2,651,481.72. This represents a 18.71% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Robert Glassman sold 8,667 shares of Pharvaris stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $38.27, for a total transaction of $331,686.09. Following the completion of the sale, the director owned 10,500 shares of the company's stock, valued at $401,835. This trade represents a 45.22% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 221,112 shares of company stock worth $8,213,772 over the last quarter. Company insiders own 11.84% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on PHVS. Oppenheimer reissued an "outperform" rating and issued a $75.00 price objective on shares of Pharvaris in a research report on Tuesday, September 8th. Royal Bank Of Canada boosted their target price on Pharvaris from $52.00 to $62.00 and gave the company an "outperform" rating in a research report on Wednesday, September 9th. HC Wainwright reaffirmed a "buy" rating and set a $60.00 target price on shares of Pharvaris in a research note on Tuesday, September 8th. Weiss Ratings reissued a "sell (d-)" rating on shares of Pharvaris in a research note on Friday, July 17th. Finally, Citigroup restated a "market outperform" rating on shares of Pharvaris in a report on Wednesday, September 9th. Thirteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $59.87.

Pharvaris Profile

Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.

Pharvaris' lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.